secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001493152-24-020460
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell raises $5.0M in registered direct offering with warrants; director participates
--------------------------------------------------------------------------------

- Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.
- Combined purchase price: $2.00/share for institutional investors; $2.215/share for a director of the company.
- Warrants exercisable at $2.11/share, beginning 6 months from issuance, expiring in 5 years.
- Net proceeds to fund working capital and Phase 3 pivotal study in advanced breast cancer.
- Closing occurred May 17, 2024; placement agent A.G.P./Alliance Global Partners received 7% fee and 50,000 warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/0001493152-24-020460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer